Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446977 | 0.94 | TRPM8 (0.40) | TRPM8 | |
| SCHEMBL2445149 | 0.83 | TRPM8 (0.43) | TRPM8 | |
| SCHEMBL19580121 | 0.78 | TRPM8 (0.43) | TRPM8 | |
| SCHEMBL2445022 | 0.76 | TRPM8 (0.47) | TRPM8 | |
| SCHEMBL2450499 | 0.75 | TRPM8 (0.66) | TRPM8 | |
| SCHEMBL2487356 | 0.71 | TRPM8 (0.47) | TRPM8 | |
| SCHEMBL2451463 | 0.71 | TRPM8 (0.60) | TRPM8 | |
| SCHEMBL2451470 | 0.71 | TRPM8 (0.60) | TRPM8 | |
| SCHEMBL2445898 | 0.68 | TRPM8 (0.74) | TRPM8 | |
| Trifluoroacetic Acid SCHEMBL2445440 | 0.68 | TRPM8 (0.64) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542552-B1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-15 | — | — | EP | disclosed |
| US-9718820-B2 | Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-01 | — | — | US | disclosed |
| US-20160304518-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-20 | — | — | US | disclosed |
| US-9409915-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-09 | — | — | US | disclosed |
| US-20150158875-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | US | disclosed |
| US-9023846-B2 | Substituted AZA-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20140155395-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-05 | — | — | US | disclosed |
| US-8680098-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304518-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | TRPM8 1/4885 |
| US-20150158875-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | TRPM8 1/4885 |
| US-20140155395-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | TRPM8 1/4885 |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | TRPM8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.